Journals / Turkish Neurosurgery / 2016 / Cilt: 26 - Sayı: 5

Use of Levetiracetam in Prophylaxis of Early Post-Traumatic Seizures

Pages
732–735
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further larger prospective studies are required to improve the evidence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Traumatic brain injury is one of the leading causes of mortality and morbidity worldwide.
📊
Key Findings & Data:MATERIAL and METhODS: This was a retrospective cohort study done at the department of neurosurgery of Aga Khan University in Karachi from July 2010 to March 2011.
💡
Conclusion & Impact:Further larger prospective studies are required to improve the evidence.
🔬Design:Review & Systematic Survey
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Özet

AIM: Traumatic brain injury is one of the leading causes of mortality and morbidity worldwide. The role of prophylactic anti-epileptic drugs has been established. Phenytoin used traditionally for this purpose carries a burden of adverse reactions and cumbersome need of monitoring and maintaining levels in serum. Therefore, as the evidence on levetiracetam, emerged part of neurosurgery section started using this drug for seizure prophylaxis after early loading with phenytoin. So we decided to assess the use of enteral levetiracetam in prophylaxis of early post-traumatic seizures. MATERIAL and METhODS: This was a retrospective cohort study done at the department of neurosurgery of Aga Khan University in Karachi from July 2010 to March 2011. Charts of patients who were started on levetiracetam enterally were reviewed and followed for occurrence of clinical seizures within one week of trauma. The results were then compared to the group of patients treated prophylactically with phenytoin alone over the same time period. RESULTS: The study included 50 patients in each group. Both groups were comparable in terms of demographics and baseline characteristics. However, 2 patients in each group suffered from clinical seizures with a non-significant p value. CONCLUSION: Enteral levetiracetam after initial phenytoin loading is a viable option in the armamentarium of anti-epileptic drugs. Further larger prospective studies are required to improve the evidence.

🔖

Cite This Article

JAVED, G., WAQAS, M., QADEER, M., BARI, E., MURTAZA, G. (2016). Use of Levetiracetam in Prophylaxis of Early Post-Traumatic Seizures. Turkish Neurosurgery, Cilt: 26 - Sayı: 5, 732–735. https://ajindex.com/articles/404658

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Anderson GD, Lin Y, Temkin NR, Fischer JH, Winn HR: Incidence of intravenous site reactions in neurotrauma patients receiving valproate or phenytoin. Ann Pharmacother 34:697-702, 2000 2. Bullock MR, Povlishock JT: Guidelines for the management of severe traumatic brain injury. Editor's Commentary. J Neurotrauma 24 Suppl 1:2, 2007 3. Bullock R, Chesnut R, Clifton G, Ghajar J, Marion D, Narayan R, Newell D, Pitts L, Rosner M, Wilberger J: Guidelines for the management of severe head injury. Eur J Emerg Med 3:109- 127, 1996 4. Carnes MB, Axlund TW, Boothe DM: Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. Am J Vet Res 72:1247- 1252, 2011 5. Gabl M, Kostron H: Diphenylhydantoin induced granulocytopenia following a seizure prophylaxis after a depressed skull fracture. Zentralbl Neurochir 47:339-341, 1986 6. Guerra IC, Fawcett WA 4th, Redmon AH, Lawrence EC, Rosenblatt HM, Shearer WT: Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity. J Allergy Clin Immunol 77:603-607, 1986 7. Guidelines for the management of severe head injury. Brain Trauma Foundation, American Association of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care. J Neurotrauma 13:641-734, 1996 8. Haltiner AM, Temkin NR, Winn HR, Dikmen SS: The impact of posttraumatic seizures on 1-year neuropsychological and psychosocial outcome of head injury. J Int Neuropsychol Soc 2:494-504, 1996 9. Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, Stippler M, Fischer M, Sauber-Schatz EK, Fabio A, Darby JM, Okonkwo DO: Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus 25:E3, 2008 10. Patel NC, Landan IR, Levin J, Szaflarski J, Wilner AN: The use of levetiracetam in refractory status epilepticus. Seizure 15:137-141, 2006 11. Patsalos PN: Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43:707-724, 2004 12. Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, Roberts I, Shakur H, Steyerberg E, Yutthakasemsunt S: Predicting outcome after traumatic brain injury: Practical prognostic models based on large cohort of international patients. BMJ 336:425-429, 2008 13. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A: Levetiracetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47:1128-1135, 2006 14. Ramael S, De Smedt F, Tou